For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
HOME > REGULATORY
REGULATORY
- MHLW Approves 23 Products Including Toviaz
December 26, 2012
- LDP to Finalize Tax Reform Outline for FY2013 by Late January
December 26, 2012
- OTC Switching of Life Style Disease Treatments on Different Level from that of Conventional Treatments: JMA Vice President Nakagawa
December 25, 2012
- MHLW to Establish a Venue for Discussions to Review Policies for OTC Switching of Lifestyle Disease Treatments
December 21, 2012
- Osaka’s Healthcare Plan Highlights Differences in Definition of “Frequent Deliveries”
December 21, 2012
- PAC Approves OTC Switching of Epadel
December 21, 2012
- CSIMC Recommends New Rules on Reducing Prices of Long-Listed Drugs
December 21, 2012
- MHLW to Revise and Consider Legislation of Ethical Guidelines for Clinical Research
December 20, 2012
- DPJ Loses Big, Nagatsuma Only Health Minister Veteran to Retain Seat
December 19, 2012
- Pharmaceutical Industry Welcomes Incoming Abe Administration
December 19, 2012
- MHLW Invites Applicants for Developing New Flu Vaccine Using Cell Culture Method Due to BIKEN Withdrawal
December 18, 2012
- PFSB Issues First Guidance on Quality Evaluation of Antibody Drugs
December 18, 2012
- Health Minister Mitsui Loses Seat in Lower House Election
December 18, 2012
- LDP Wins Landslide in Lower House Election, Social Security Bigwigs Reinstated
December 18, 2012
- 60% Rule Applied to 5 APIs in December Generic Listing
December 14, 2012
- Mr Sato of PFSB Stresses Need for MAH to Strengthen Ties, Communications with Overseas Drug Substance Manufacturers: PDA Japan Annual Meeting
December 14, 2012
- Strategy Council Proposes Revamped Framework to Oversee Entire Life Innovation Budgets
December 12, 2012
- PMDA Taking Public Comments on Proposed Revisions of the Japanese Pharmacopoeia
December 12, 2012
- Generic Drug Use Rising at DPC Hospitals: MHLW
December 11, 2012
- MHLW Puzzled at “Opaque” GRU Recommendation after Project Screening
December 10, 2012
ページ
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…